

CITATION REPORT

List of articles citing

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

DOI: 10.1097/00006982-200603000-00005
Retina, 2006, 26, 279-84.

Source: <https://exaly.com/paper-pdf/40198481/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
440	New pharmacologic approaches to therapy for age-related macular degeneration. 2006 , 20, 167-79		29
439	Promising new treatments for neovascular age-related macular degeneration. 2006 , 15, 779-93		51
438	Intravitreal avastin: the low cost alternative to lucentis?. 2006 , 142, 141-3		102
437	Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. 2006 , 47, 4569-78		135
436	Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. <i>Retina</i> , 2006 , 26, 512-8	3.6	96
435	Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. <i>Retina</i> , 2006 , 26, 877-81	3.6	52
434	Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). <i>Retina</i> , 2006 , 26, 1006-13	3.6	208
433	Expanding treatment options in age-related macular degeneration. 2006 , 46, 123-9		9
432	Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. <i>Retina</i> , 2006 , 26, 999-1005	3.6	380
431	Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. 2006 , 84, 555-6		47
430	Intravitreal bevacizumab for branch retinal vein occlusion. 2007 , 85, 118-9		24
429	Bevacizumab: a new way of doing business?. 2006 , 20, 985-7		3
428	[Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. 2006 , 103, 471-5		57
427	Opaque coating of an intraocular lens and regression of iris neovascularization following injection of triamcinolone acetonide into the anterior chamber. 2006 , 34, 803-5		2
426	Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). 2006 , 34, 802-3		35
425	Evolving European guidance on the medical management of neovascular age related macular degeneration. 2006 , 90, 1188-96		49
424	The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. 2006 , 90, 1344-9		405

423	Some ethical considerations for the "off-label" use of drugs such as Avastin. 2006 , 90, 1218-9	5
422	Is intravitreal bevacizumab (Avastin) safe?. 2006 , 90, 1333-4	15
421	Potential future treatment strategies for retinal vein occlusion. 2006 , 1, 77-82	1
420	Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. 2006 , 90, 1316-21	87
419	Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. 2007 , 42, 335-336	1
418	Bevacizumab for ophthalmic diseases. 2007 , 2, 369-378	2
417	Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration. 2007 , 23, 599-600	15
416	Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. 2007 , 23, 387-94	15
415	Central retinal vein occlusion: the therapeutic options. 2007 , 42, 193-195	
414	Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. 2007 , 23, 240-2	56
413	Role of intravitreal bevacizumab in neovascular glaucoma. 2007 , 23, 487-91	64
412	Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. 2007 , 91, 1244-6	112
411	Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. 2007 , 91, 1644-9	113
410	The role of topical antibiotic prophylaxis for intravitreal injections. 2007 , 125, 974-6	15
409	Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. 2007 , 48, 1773-81	92
408	Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. 2007 , 125, 751-6	100
407	Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. 2007 , 125, 1363-6	72
406	Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. <i>Retina</i> , 2007 , 27, 701-6 ^{3.6}	36

405	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR TREATMENT OF PERSISTENT MACULAR EDEMA IN VITRECTOMIZED EYES: Limited Effect and Early Recurrence. 2007 , 1, 195-7		7
404	Treating Neovascular Glaucoma With Intravitreal Bevacizumab. 2007 , 5, 150-153		
403	Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. <i>Retina</i> , 2007 , 27, 133-40	3.6	170
402	Drug delivery methods for posterior segment disease. 2007 , 18, 235-9		70
401	Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. <i>Retina</i> , 2007 , 27, 141-9	3.6	166
400	Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. <i>Retina</i> , 2007 , 27, 426-31	3.6	107
399	Intravitreal bevacizumab (avastin) in central retinal vein occlusion. <i>Retina</i> , 2007 , 27, 1013-9	3.6	63
398	Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. <i>Retina</i> , 2007 , 27, 1004-12	3.6	100
397	Safety profile of bevacizumab on cultured human corneal cells. 2007 , 26, 977-82		83
396	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. <i>Retina</i> , 2007 , 27, 419-25	3.6	212
395	Bibliography. Current world literature. Retinal, vitreous and macular disorders. 2007 , 18, 245-77		
394	Intravitreal Bevacizumab (Avastin) for the Treatment of Chorioretinal Vascular Diseases. 2007 , 5, 40-45		
393	Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 2007 , 16, 437-9		81
392	Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. <i>Retina</i> , 2007 , 27, 535-40	3.6	54
391	Intravitreal bevacizumab. 2007 , 114, 400; author reply 400-1		1
390	Author reply. 2007 , 114, 399-400		1
389	Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. 2007 , 114, 743-50		279
388	Interventions for branch retinal vein occlusion: an evidence-based systematic review. 2007 , 114, 835-54		118

387	Pharmacokinetics of intravitreal bevacizumab (Avastin). 2007 , 114, 855-9	560
386	Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. 2007 , 114, 2168-73	174
385	Pharmacokinetics of intravitreal ranibizumab (Lucentis). 2007 , 114, 2179-82	425
384	Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. 2007 , 143, 601-6	149
383	Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. 2007 , 144, 124-6	102
382	Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. 2007 , 144, 126-8	44
381	Central retinal vein occlusion case-control study. 2007 , 144, 858-863	70
380	Early bevacizumab treatment of central retinal vein occlusion. 2007 , 144, 864-71	104
379	Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. 2007 , 33, 2098-105	45
378	Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. 2007 , 16, 1209-26	35
377	Bevacizumab for neovascular ocular diseases. 2007 , 41, 614-25	137
376	[Medical treatment of macular edema]. 2007 , 30, 748-56	1
375	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. 2007 , 91, 128-30	8
374	Molecular targets for retinal vascular diseases. 2007 , 210, 575-81	37
373	Intravitreal injection: balancing the risks. 2007 , 21, 313-6	5
372	Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. 2007 , 21, 1128-30	16
371	Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. 2007 , 85, 461-3	33
370	[Intravitreal bevacizumab for recurring choroidal neovascularisation]. 2007 , 104, 158-60	4

369	[Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. 2007 , 104, 285-9	36
368	Progenitor cells and retinal angiogenesis. 2007 , 10, 89-101	51
367	Differentialdiagnose und Therapie retinaler Gefäßerschlüsse. 2007 , 21, 118-127	
366	Systemisches und intravitreales Bevacizumab (Avastin®) bei neovaskulärer altersbezogener Makuladegeneration. 2007 , 21, 154-159	1
365	Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). 2007 , 245, 1273-80	45
364	Bevacizumab in retinal vein occlusion-results of a prospective case series. 2007 , 245, 1429-36	90
363	Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. 2008 , 116, 129-35	29
362	Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. 2008 , 116, 147-52	35
361	[OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion]. 2008 , 105, 1121-6	8
360	Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). 2008 , 246, 837-42	137
359	Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. 2008 , 246, 1241-7	80
358	Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. 2008 , 246, 1787-9	21
357	Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. 2008 , 8, 18	20
356	Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. 2008 , 217, 13-22	56
355	Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). 2008 , 86, 385-9	97
354	Complications in patients after intravitreal injection of bevacizumab. 2008 , 86, 372-6	150
353	Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. 2008 , 22, 1168-71	28
352	Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. <i>Molecular Therapy</i> , 2008 , 16, 791-9	11.7 253

351	Intravitreal steroids for macular edema: the past, the present, and the future. 2008 , 53, 139-49		113
350	Surgical treatment of central retinal vein occlusion. 2008 , 86, 245-52		27
349	Intravitreal bevacizumab treatment for refractory diabetic macular edema. 2008 , 24, 403-7		7
348	Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. 2008 , 33, 111-31		286
347	Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. 2008 , 92, 213-6		296
346	Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. 2008 , 92, 1424-8		14
345	Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. 2008 , 92, 351-5		80
344	Bevacizumab sterility in multiple doses from a single-use vial. 2008 , 42, 1425-8		19
343	Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. 2008 , 92, 518-22		139
342	Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. 2008 , 225, 397-400		9
341	The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin). 2008 , 225, 380-4		6
340	Needle Bleb Revision With Bevacizumab. 2008 , 6, 111-113		
339	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. 2008 ,		4
338	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. 2008 ,		2
337	A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion. 2008 , 5, 64-71		
336	Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. <i>Retina</i> , 2008 , 28, 1053-60	3.6	139
335	Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. <i>Retina</i> , 2008 , 28, 564-7	3.6	128
334	Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. 2008 , 27, 1151-5		18

333	Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. <i>Retina</i> , 2008 , 28, 1325-37	3.6	31
332	Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. <i>Retina</i> , 2008 , 28, 1319-24	3.6	43
331	Induction of retinochoroidal venous anastomosis in central retinal vein occlusion with macular edema via a full-thickness retinochoroidal incision. <i>Retina</i> , 2008 , 28, 477-84	3.6	1
330	Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. <i>Retina</i> , 2008 , 28, 212-9	3.6	88
329	Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). <i>Retina</i> , 2008 , 28, 964-8	3.6	71
328	Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. <i>Retina</i> , 2008 , 28, 957-63	3.6	90
327	Integrity of foveal photoreceptor layer in central retinal vein occlusion. <i>Retina</i> , 2008 , 28, 1502-8	3.6	91
326	Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. <i>Retina</i> , 2008 , 28, 1387-94	3.6	53
325	The treatment of branch retinal vein occlusion with bevacizumab. 2008 , 19, 234-8		33
324	Cystoid macular edema. <i>Clinical Ophthalmology</i> , 2008 , 2, 919-30	2.5	95
323	Two Cases of Subconjunctival Bevacizumab Injection to Prevent Bleb Failure After Trabeculectomy. <i>Journal of Korean Ophthalmological Society</i> , 2008 , 49, 1345	0.2	1
322	Retinal Choroidal Collateral Circulation After Radial Optic Neurotomy for Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2008 , 49, 456	0.2	
321	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2008 , 2, 787-91	2.5	9
320	Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema. <i>Journal of Korean Ophthalmological Society</i> , 2008 , 49, 1275	0.2	6
319	Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2009 , 50, 1800	0.2	3
318	Therapeutic Effects of Intravitreal Bevacizumab Injection for Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2009 , 50, 1359	0.2	1
317	The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema. <i>Journal of Korean Ophthalmological Society</i> , 2009 , 50, 1232	0.2	
316	Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. 2009 , 23, 259-65		26

315	Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema. 2009 , 2009, 672178	5
314	Intravitreal bevacizumab for treatment of diabetic macular edema. 2009 , 23, 17-22	17
313	Intravitreal bevacizumab for diabetic retinopathy. 2009 , 5, 39-46	45
312	The effects of injection site on the reflux following intravitreal injections. 2009 , 1, 280-4	8
311	Effect of intravitreal bevacizumab (avastin) on the growing rabbit eye. 2009 , 34, 660-5	7
310	Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. 2009 , 25, 259-64	10
309	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. 2009 , CD007419	22
308	Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. 2009 , 93, 1027-32	24
307	Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. 2009 , 50, 1025-32	176
306	Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. 2009 , 127, 374-80	70
305	Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. 2009 , 93, 452-6	162
304	Early intravitreal bevacizumab for non-ischaeamic branch retinal vein occlusion. 2009 , 223, 124-7	28
303	Off with the label and on the Avastin bandwagon: why now and how far?. <i>Indian Journal of Ophthalmology</i> , 2009 , 57, 253-6	1.6 2
302	Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis. 2009 , 17, 56-8	6
301	Laser photocoagulation and intravitreal injection of triamcinolone for retinal vein occlusions. 2009 , 302, 1693-5	2
300	Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion. 2009 , 37, 208-16	22
299	Physiology of vitreous surgery. 2009 , 247, 147-63	189
298	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. 2009 , 247, 735-43	69

297	Measurement of PO ₂ during vitrectomy for central retinal vein occlusion, a pilot study. 2009 , 247, 1019-23	43
296	Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. 2009 , 247, 1609-16	25
295	Acute endophthalmitis caused by <i>Staphylococcus lugdunensis</i> after intravitreal bevacizumab (Avastin) injection. 2009 , 29, 411-3	8
294	Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. 2009 , 29, 343-8	15
293	Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. 2009 , 118, 81-8	13
292	A multimodal approach to eye melanoma: patterns of care and related complications. 2009 , 3, 41-49	
291	[Intraocular injections of bevacizumab in rare indications--two cases]. 2009 , 106, 435-42	2
290	Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. 2009 , 23, 117-23	91
289	Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan. 2009 , 23, 849-57	13
288	Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. 2009 , 23, 2215-22	22
287	Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. 2009 , 23, 2023-33	28
286	Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. 2009 , 88, 418-25	40
285	Bevacizumab (Avastin) for the treatment of ocular disease. 2009 , 54, 372-400	114
284	Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 2009 , 116, 87-93	176
283	Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. 2009 , 116, 1151-7	69
282	Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. 2009 , 116, 1488-97, 1497.e1	105
281	SCORE Study report 3: study design and baseline characteristics. 2009 , 116, 1770-1777.e1	35
280	Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. 2009 , 116, 1481-7, 1487.e1	74

279	Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. 2009 , 116, 2415-21		44
278	Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. 2009 , 147, 298-306		140
277	Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. 2009 , 147, 627-633.e1		33
276	Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. 2009 , 147, 1022-30, 1030.e1-5		27
275	Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma. 2009 , 80, 243-8		5
274	Retinal Angiography and Optical Coherence Tomography. 2009 ,		12
273	Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. 2009 , 127, 381-9		157
272	[Retinal vein occlusion: anti-VEGF treatments]. 2009 , 32, 679-86		10
271	The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. 2009 , 44, 154-9		16
270	Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. 2009 , 50, 4905-16		29
269	Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. 2009 , 34, 231-7		38
268	Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. 2009 , 25, 545-50		29
267	Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. 2009 , 87, 285-9		17
266	Early intravitreal bevacizumab for non-ischaeamic central retinal vein occlusion. 2009 , 87, 77-81		28
265	Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. 2009 , 87, 623-30		34
264	The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. <i>Retina</i> , 2009 , 29, 20-6	3.6	32
263	Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. <i>Retina</i> , 2009 , 29, 8-12	3.6	77
262	Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. <i>Retina</i> , 2009 , 29, 33-7	3.6	42

261	Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. <i>Retina</i> , 2009 , 29, 757-67	3.6	36
260	Bevacizumab in macular edema: functional and anatomic changes in a prospective case series. <i>Retina</i> , 2009 , 29, 941-8	3.6	4
259	Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein. <i>Retina</i> , 2009 , 29, 1167-74	3.6	14
258	Intravitreal injection of therapeutic agents. <i>Retina</i> , 2009 , 29, 875-912	3.6	173
257	Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. 2009 , 18, 632-7		67
256	Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. <i>Retina</i> , 2009 , 29, 932-40	3.6	28
255	Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. <i>Retina</i> , 2009 , 29, 292-9	3.6	72
254	Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. <i>Retina</i> , 2009 , 29, 313-8	3.6	94
253	Anti-VEGF therapy in proliferative diabetic retinopathy. 2009 , 49, 95-107		28
252	A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. 2009 , 127, 1101-14		378
251	Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. <i>Retina</i> , 2009 , 29, 511-5	3.6	93
250	Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. <i>Retina</i> , 2009 , 29, 1274-81	3.6	9
249	Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetate or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography. <i>Retina</i> , 2010 , 30, 495-502	3.6	16
248	The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. <i>Retina</i> , 2010 , 30, 570-7	3.6	21
247	Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. <i>Retina</i> , 2010 , 30, 1002-11	3.6	39
246	Anti-VEGF therapy for glaucoma. 2010 , 21, 112-7		63
245	Vitreous levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreous VEGF and the extent of macular edema. <i>Retina</i> , 2010 , 30, 1524-9	3.6	26
244	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. 2010 , CD007325		22

243	[Position of the German Society of Ophthalmology, the Retinal Society and the German Professional Association of Ophthalmologists on therapy of macular edema in retinal vein occlusion]. 2010 , 107, 583-95		2
242	Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. 2010 , 248, 155-9		70
241	Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. 2010 , 248, 375-80		28
240	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. 2010 , 248, 785-91		79
239	Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion. 2010 , 54, 555-64		10
238	Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. 2010 , 30, 15-22		33
237	Protein delivery for retinal diseases: from basic considerations to clinical applications. 2010 , 29, 443-65		63
236	The capsule drug device: novel approach for drug delivery to the eye. 2010 , 50, 680-5		40
235	Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. 2010 , 24, 810-5		29
234	Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. 2010 , 24, 1284-90		27
233	Short-term Effects of Intravitreal Bevacizumab Injection and Macular Edema Patterns in Branch Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2010 , 51, 379	0.2	4
232	Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2010 , 51, 707	0.2	6
231	The Effect of Subconjunctival Injection of Bevacizumab After Resection of Muscle in Rabbit Models. <i>Journal of Korean Ophthalmological Society</i> , 2010 , 51, 423	0.2	2
230	Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. 2010 , 20, 402-9		62
229	Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. 2010 , 20, 180-5		17
228	Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2010 , 51, 1071	0.2	5
227	Monoclonal antibodies in rare acquired thrombotic disorders: the paradigms of paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura and central retinal vein occlusion. 2010 , 8, 51-8		1
226	Retinal vein occlusions. 2010 , 47, 111-135		65

225	Retinal arteriovenous malformation presenting with retinal vein occlusion during pregnancy. 2010 , 4, 112-5	2
224	Rebound neovascularization during bevacizumab therapy. 2010 , 4, 216-9	1
223	Intravitreal triamcinolone and bevacizumab therapy for combined papillophlebitis and central retinal artery occlusion. 2010 , 4, 125-8	2
222	Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury. 2010 , 51, 5920-33	62
221	Visual acuity and foveal thickness after vitrectomy for macular edema. 2010 , 224, 367-73	14
220	Results of bevacizumab as the primary treatment for retinal vein occlusions. 2010 , 94, 1052-6	59
219	Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion. 2010 , 26, 325-8	15
218	Oclusiones venosas retinales. 2010 , 21, 961-965	1
217	Applications of nanobiotechnology in ophthalmology--Part I. 2010 , 44, 1-16	7
216	Effects of bevacizumab on apoptosis, Na ⁺ -K ⁺ -adenosine triphosphatase and zonula occludens 1 expression on cultured corneal endothelial cells. 2010 , 44, 43-9	6
215	Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. 2010 , 128, 1273-9	157
214	[Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on Therapy for Macular Oedema in Cases of Retinal Vein Occlusion]. 2010 , 227, 542-56	7
213	[Intravitreal drug therapy for retinal vein occlusion--pathophysiological mechanisms and routinely used drugs]. 2010 , 227, 681-93	12
212	SERV clinical practice guidelines: Management of retinal vein occlusion. 2010 , 85, 294-309	
211	Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab. 2010 , 85, 364-369	
210	Long-term clinical outcome of radial optic neurotomy. 2010 , 85, 370-375	
209	Aqueous humor nitric oxide in patients with central retinal vein occlusion. 2010 , 23, 332-4	8
208	[Long-term clinical outcome of radial optic neurotomy]. 2010 , 85, 370-5	3

207	[Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab]. 2010 , 85, 364-9	10
206	[SERV clinical practice guidelines: management of retinal vein occlusion. Sociedad Española de Retina y Vitreo]. 2010 , 85, 294-309	4
205	Severe intraocular inflammation after intravitreal injection of bevacizumab. 2010 , 117, 512-6, 516.e1-2	55
204	The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. 2010 , 117, 954-65	46
203	Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. 2010 , 117, 1974-81, 1981.e1	26
202	Natural history of central retinal vein occlusion: an evidence-based systematic review. 2010 , 117, 1113-1123.e157	157
201	Early Avastin management in acute retinal vein occlusion. 2010 , 24, 87-94	4
200	Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. 2010 , 24, 133-8	20
199	Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. 2010 , 150, 310-4	67
198	Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions. 2010 , 88, e24-5	6
197	Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. 2010 , 88, 646-51	25
196	Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. 2010 , 45, 386-92	16
195	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. 2010 , 45, 501-8	5
194	Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 2011 , 36, 256-63	31
193	Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 2011 , 36, 1164-70	12
192	ACV isquémico asociado a inyección intravítrea de bevacizumab. 2011 , 3, 64-67	
191	Steroids and macular edema from retinal vein occlusion. 2011 , 21 Suppl 6, S37-44	12
190	Management of retinal vein occlusion--consensus document. 2011 , 226, 4-28	88

189	Economic considerations of macular edema therapies. 2011 , 118, 1827-33		61
188	Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion. 2011 , 89, e35-40		47
187	Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. 2011 , 89, e567-72		46
186	Occlusions veineuses riniennes. 2011 , 107-130		
185	The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2011 , 52, 1048	0.2	3
184	Correlation between spectral domain optical coherence tomography findings and visual outcomes in central retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2011 , 5, 299-305	2.5	12
183	Clinical Course after Intravitreal Bevacizumab Injection in Ischemic Central Retinal Vein Obstruction. <i>Journal of Korean Ophthalmological Society</i> , 2011 , 52, 1202	0.2	
182	Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. <i>Clinical Ophthalmology</i> , 2011 , 5, 745-9	2.5	17
181	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer. <i>Clinical Ophthalmology</i> , 2011 , 5, 1217-9	2.5	4
180	Focal macular electroretinogram in macular edema secondary to central retinal vein occlusion. 2011 , 52, 3514-20		11
179	Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab. <i>Clinical Ophthalmology</i> , 2011 , 5, 771-81	2.5	13
178	Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes. 2011 , 52, 5737-42		24
177	Electroretinographic Assessment of the Retinal Function during Intravitreal Bevacizumab Injections in Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2011 , 52, 1055	0.2	0
176	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. 2011 , 2011, 584238		33
175	Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. <i>Retina</i> , 2011 , 31, 821-8	3.6	19
174	Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. 2011 , 20, 196-201		51
173	Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography. <i>Retina</i> , 2011 , 31, 829-37	3.6	102
172	Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections. <i>Retina</i> , 2011 , 31, 1863-70	3.6	4

171	A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. <i>Retina</i> , 2011 , 31, 1449-69	3.6	112
170	Ranibizumab for the treatment of macular edema following retinal vein occlusion. 2011 , 1, 1445-1454		1
169	Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study. 2011 , 25, 239-44		12
168	On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. 2011 , 100, 1523-7		66
167	Influence of vitreous factors after vitrectomy for macular edema in patients with central retinal vein occlusion. 2011 , 31, 393-402		6
166	Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. 2011 , 249, 273-80		7
165	Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion. 2011 , 249, 513-20		8
164	Vitreous inflammatory factors in macular edema with central retinal vein occlusion. 2011 , 55, 248-255		36
163	Negative correlation between aqueous vascular endothelial growth factor levels and axial length. 2011 , 55, 401-404		24
162	The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. 2011 , 27, 611-4		17
161	Corneal penetration of topical and subconjunctival bevacizumab. 2011 , 52, 8718-23		76
160	Simultaneous intravitreal injection of triamcinolone acetonide and tissue plasminogen activator for central retinal vein occlusion: a pilot study. 2011 , 95, 69-73		3
159	Tissue kallikrein inhibits retinal neovascularization via the cleavage of vascular endothelial growth factor-165. 2011 , 31, 1041-8		27
158	Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. 2011 , 52, 3334-7		43
157	Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. 2011 , 52, 8944-50		33
156	Retinal vein occlusion: current treatment. 2011 , 225, 135-43		21
155	Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. 2011 , 95, 56-68		24
154	Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. 2011 , 95, 788-92		34

153	Angioedema after intravitreal bevacizumab injection. 2012 , 31, 85-6		4
152	Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. 2012 , 28, 559-65		5
151	Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema. 2012 , 28, 69-75		7
150	Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. 2012 , 96, 14-20		134
149	Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. 2012 , 53, 5877-80		74
148	Changes in visual acuity and foveal photoreceptor integrity in eyes with chronic cystoid macular edema associated with retinal vein occlusion. <i>Retina</i> , 2012 , 32, 792-8	3.6	12
147	Disrupted foveal photoreceptors after combined cystoid spaces and retinal detachment in branch vein occlusion treated with bevacizumab. <i>Retina</i> , 2012 , 32, 1853-61	3.6	7
146	Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). 2012 , 10, 67-83		103
145	[Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide]. 2012 , 35, 700-4		
144	Factors promoting success and influencing complications in laser-induced central vein bypass. 2012 , 119, 2579-86		9
143	Phacoemulsification with intravitreal bevacizumab injection in patients with cataract and coexisting diabetic retinopathy: prospective randomized study. 2012 , 28, 212-8		10
142	Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. 2012 , 153, 1116-24.e1		50
141	Intravitreal pegaptanib sodium (Macugen [®]) for treatment of diabetic macular oedema: a morphologic and functional study. 2012 , 74, 940-6		17
140	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. 2012 , 12, CD007419		54
139	Short-term topical bevacizumab in the treatment of stable corneal neovascularization. 2012 , 154, 940-948.e1		38
138	Anti-vascular endothelial growth factor treatment for retinal vein occlusions. 2012 , 227 Suppl 1, 30-5		49
137	Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. 2012 , 227, 132-8		11
136	Current therapy for retinal vein occlusion. 2012 , 113, 228-31		2

135	Short-Term Visual Outcomes According to Patterns of Macular Edema in Retinal Vein Occlusion Patients. <i>Journal of Korean Ophthalmological Society</i> , 2012 , 53, 1276	0.2	2
134	Evaluation of ultrasound-assisted thrombolysis using custom liposomes in a model of retinal vein occlusion. 2012 , 53, 6920-7		3
133	Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion. 2012 , 250, 635-44		19
132	Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. 2012 , 250, 1149-60		25
131	Central retinal vein occlusion: a review. 2012 , 40, 48-58		43
130	Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. 2013 , 27, 25-9		10
129	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. 2013 , 27, 55-7		4
128	Visual prognostic value of photopic negative response and optical coherence tomography in central retinal vein occlusion after anti-VEGF treatment. 2013 , 126, 211-9		7
127	Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion. 2013 , 156, 543-547.e1		56
126	Retinal venous occlusions: diagnosis and choice of treatments. 2013 , 49, 215-22		12
125	A clinical study to evaluate the efficacy of intravitreal Anti-VEGF therapy in treating macular edema due to retinal venous occlusions. 2013 , 69, 260-7		2
124	Recent advances in the management of neovascular glaucoma. 2013 , 28, 165-72		38
123	Longitudinal morphometric analysis of epiretinal membrane in patients with uveitis. 2013 , 21, 2-7		10
122	Effect of bevacizumab (Avastin (TM)) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells. <i>Indian Journal of Ophthalmology</i> , 2013 , 61, 705-10	1.6	11
121	Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. 2013 , 49, 30-6		10
120	Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. 2013 , 20, 51-5		11
119	Comparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion. 2013 , 2013, 141279		5
118	Meta-analysis of the effect of intravitreal bevacizumab versus intravitreal triamcinolone acetate in central retinal vein occlusion. 2013 , 29, 826-31		4

117	Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. <i>Retina</i> , 2013 , 33, 56-62	3.6	38
116	Progressive optic nerve collateralization after serial intravitreal ranibizumab injections for central retinal vein occlusion. <i>Retina</i> , 2013 , 33, 449-50	3.6	2
115	Topical ranibizumab as a treatment of corneal neovascularization. 2013 , 32, 992-7		54
114	Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. 2013 , 3, 40-69		20
113	Short term results of intra-vitreous bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. 2013 , 5, 63-8		2
112	Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients. <i>Clinical Ophthalmology</i> , 2013 , 7, 455-60	2.5	7
111	Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2013 , 7, 1497-501	2.5	5
110	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab Injection. <i>Journal of Korean Ophthalmological Society</i> , 2014 , 55, 780	0.2	
109	Intravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse. 2014 , 3, 3		24
108	Spectral-domain optical coherence tomography for macular edema. 2014 , 2014, 191847		7
107	A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. 2014 , 45, 521-4		20
106	Comparison between Simultaneous Intracameral and Intravitreal Injection and Intravitreal Injection of Bevacizumab in Neovascular Glaucoma. <i>Journal of Korean Ophthalmological Society</i> , 2014 , 55, 1039	0.2	1
105	Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2014 , 8, 2301-5	2.5	7
104	Pharmacotherapy for treatment of retinal vein occlusion. 2014 , 15, 2373-84		9
103	Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. 2014 , 98 Suppl 1, i11-16		80
102	Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. 2014 , 33, 275-82		7
101	İntravitreal Bevacizumab'ın Sİn Retina Hİrelerinde Apoptozis İerine Etkileri. 2014 , 44, 39-44		
100	Effect of a single intravitreal bevacizumab injection on contrast sensitivity and macular thickness in eyes with macular edema from central retinal vein occlusion: a prospective, nonrandomized, three-month follow-up study. 2014 , 51, 140-5		6

99	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. 2014 , 7, 375-91		18
98	Anti-vascular endothelial growth factor for diabetic macular oedema. 2014 , CD007419		94
97	IV.A. Vitreous Physiology. 2014 , 437-457		0
96	Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. 2014 , 30, 512-6		4
95	The role of intraoperative bevacizumab for prevention of postoperative vitreous hemorrhage in diabetic vitreous hemorrhage. 2014 , 24, 88-93		5
94	Flicker electroretinograms before and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion. 2015 , 93, e465-8		27
93	Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. 2015 , 31, 78-86		54
92	Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab. <i>Indian Journal of Ophthalmology</i> , 2015 , 63, 25-9	1.6	5
91	Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. 2016 , 31, 542-7		5
90	Spectral domain optical coherence tomographic analysis of healthy retina in branch retinal vein occlusion and its response to antiangiogenic therapy. <i>Retina</i> , 2015 , 35, 704-14	3.6	1
89	Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. 2015 , 31, 198-203		25
88	Signs, intraoperative challenges, and management strategies during cataract surgery secondary to inadvertent intralenticular antivascular endothelial growth factor injection. 2015 , 3, 80-82		1
87	Bevacizumab revisited: its use in different mouse models of ocular pathologies. 2015 , 40, 611-21		18
86	Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma. 2016 , 25, 281-4		14
85	Volume-Rendered Optical Coherence Tomography of Retinal Vein Occlusion Pilot Study. 2016 , 165, 133-44		42
84	Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion. 2016 , 235, 106-13		8
83	Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. 2016 , 145, 412-416		13
82	The effect of intravitreal injection of vehicle solutions on form deprivation myopia in tree shrews. 2016 , 145, 289-296		17

81	Retinal Vein Occlusions. 2017 , 58, 139-167		23
80	Comparison between "early" or "late" intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six-months follow-up. 2017 , 36, 224-230		3
79	SCORE2 Report 2: Study Design and Baseline Characteristics. 2017 , 124, 245-256		17
78	Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. 2017 , 61, 67-73		7
77	Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. 2017 , 9, 5068-5074		3
76	Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions. 2017 , 6, 546-553		14
75	Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. 2018 , 18, 37		4
74	Evaluation of vitreoretinal interface changes in patients receiving intravitreal anti-VEGF therapy. 2018 , 38, 549-556		3
73	Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. 2018 , 239, 27-35		8
72	RETINAL MICROVASCULATURE AND VISUAL ACUITY AFTER INTRAVITREAL AFLIBERCEPT IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. <i>Retina</i> , 2018 , 38, 2067-2072	3.6	14
71	RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2018 , 38, 283-291	3.6	9
70	Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. 2018 , 95, 1149-1154		5
69	Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion. <i>International Journal of Ophthalmology</i> , 2018 , 11, 256-261	1.4	4
68	Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. 2018 , 2018, 1694187		14
67	Changes in Retinal Microvasculature and Visual Acuity After Antivascular Endothelial Growth Factor Therapy in Retinal Vein Occlusion. 2018 , 59, 2708-2716		30
66	9 Retinal Venous Occlusive Disease. 2018 ,		
65	Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion. 2019 , 5, 32		2
64	Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. 2019 , 126, 1424-1431		27

63	Prefilled syringes for intravitreal drug delivery. <i>Clinical Ophthalmology</i> , 2019 , 13, 701-706	2.5	15
62	[Retinal vein occlusions treated by intravitreal bevacizumab injections at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaounde] 2020 , 43, 51-58		0
61	A comparison of the effect of intravitreal dexamethasone implant on macular and branch retinal vein occlusion. A real life experience. 2020 , 30, 1106-1111		
60	Clinical observation of Dan-Hong Hua-Yu oral solution in treating retinal vein occlusion. 2020 , 99, e20173		
59	Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry. 2021 ,		0
58	Efficacy of Intravitreal Triamcinolone Acetonide in the Treatment of Macular Oedema in Retinal Vein Occlusion Refractory to Anti-VEGF Therapy - A Prospective Interventional Study from a Tertiary Care Centre in Eastern India. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021 , 8, 2083-2088		0
57	Combined Intravitreal Bevacizumab and Laser Photocoagulation to Treat Retinal Arterial Macroaneurysms. <i>Journal of Korean Ophthalmological Society</i> , 2021 , 62, 1053-1060	0.2	0
56	ASSESSMENT OF INTRAOCULAR PRESSURE FOLLOWING THE INTRAVITREAL INJECTION OF ANTI-VEGF. 52-55		
55	Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review. 2021 , 7,		1
54	Retinal Vascular Resistance Significantly Correlates With Visual Acuity After 1 Year of Anti-VEGF Therapy in Central Retinal Vein Occlusion. 2021 , 10, 19		0
53	Venous Obstructive Disease of the Retina. 2009 , 597-605		3
52	Retinal Venous Occlusive Disease. 2008 , 1755-1773		4
51	[Intraocular cytokines imbalance in retinal vein occlusion and its impact on the efficacy of anti-angiogenic therapy]. 2015 , 131, 50-58		3
50	Ranibizumab in neovascular age-related macular degeneration. 2006 , 1, 451-66		9
49	Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema. 2009 , 56, 111-5		7
48	Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. 2007 , 38, 164-6		25
47	Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. 2008 , 39, 446-54		17
46	Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. 2009 , 40, 68-70		31

45	Secondary open-angle glaucoma and central retinal vein occlusion in a patient with primary pulmonary hypertension. 2009 , 40, 50-3		14
44	Full Thickness Macular Hole Formation in a Patient with Cystoid Macular Edema Caused by CRVO Treated with Intravitreal Bevacizumab. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010 , 1-4		3
43	Hemorrhagic Macular Infarction After Intravitreal Bevacizumab for Central Retinal Vein Occlusion. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010 , 1-2		7
42	Acute anterior uveitis following intravitreal injection of bevacizumab. 2013 , 44, 25-7		14
41	Evaluation of the ability of a photocoagulator to rupture the retinal vein and Bruch's membrane for potential vein bypass in retinal vein occlusion. 2013 , 44, 268-73		5
40	Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy. <i>Indian Journal of Ophthalmology</i> , 2015 , 63, 905-11	1.6	6
39	Bevacizumab: off-label use in ophthalmology. <i>Indian Journal of Ophthalmology</i> , 2007 , 55, 417-20	1.6	47
38	The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2007 , 55, 441-3	1.6	33
37	Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. <i>Indian Journal of Ophthalmology</i> , 2007 , 55, 451-5	1.6	29
36	Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results. <i>Oman Journal of Ophthalmology</i> , 2009 , 2, 73-8	0.7	5
35	Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion. <i>Oman Journal of Ophthalmology</i> , 2009 , 2, 94-5	0.7	2
34	Changes in Retinal Nerve Fiber Layer Thickness after Two Intravitreal Bevacizumab Injections for Wet Type Age-related Macular Degeneration. <i>Journal of Ophthalmic and Vision Research</i> , 2014 , 9, 449-52 ^{1,2}		8
33	Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Chorioretinopathy: A Case Report. <i>Open Journal of Ophthalmology</i> , 2012 , 02, 93-96	0.2	1
32	Pathogenesis, prevention, diagnosis and management of retinal vein occlusion. <i>World Journal of Ophthalmology</i> , 2014 , 4, 92	0	2
31	Immunosuppression. 2008 , 1123-1136		
30	Diabetic Macular Edema. 2008 , 1793-1806		0
29	RETINAL VENOUS OBSTRUCTION 362.30. 2008 , 635-636		
28	Ranibizumab for Macular Edema Due to Retinal Vein Occlusions; Implication of VEGF as a Critical Stimulator. <i>Molecular Therapy</i> ,	11.7	2

27	Intravitreal injections. 2009 , 133-143		
26	Optic Nerve Disease in Diabetes Mellitus. 2010 , 357-368		1
25	Anti-VEGF en las oclusiones venosas retinianas. 2010 , 121-129		
24	Intravitreal Bevacizumab for Macular Edema from Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010 , 1-3		
23	Treatment of Retinal Vein Occlusions. 2012 , 279-334		
22	Ischemia and Retinal Vein Occlusions. 2012 , 223-239		
21	Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab. <i>Ophthalmic Surgery, Lasers and Imaging</i> ,		
20	EFFECT ON MACULAR EDEMA IN NON-ISCHEMIC CRVO: COMPARISON BETWEEN INTRAVITREAL BEVACIZUMAB AND COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2013 , 2, 3293-3304	0.1	
19	Stability and Sterility of Bevacizumab after Withdrawal into a Syringe and Refrigeration or Freezing. <i>Journal of Korean Ophthalmological Society</i> , 2014 , 55, 1499	0.2	1
18	Retinal Vein Occlusion. 2017 , 147-150		
17	HBO Therapy and Ophthalmology. 2017 , 457-483		
16	SAFETY AND EFFICACY OF PREOP INTRAVITREAL TRIAMCINOLONE PLUS BEVACIZUMAB COMBINATION AND BEVACIZUMAB ALONE IN VITREOUS SURGERY FOR NON-RESOLVING VITREOUS HAEMORRHAGE IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR). <i>Journal of Evidence Based Medicine and Healthcare</i> , 2019 , 4, 218-221	0	
15	Comparison of Short-term Effects of Intravitreal Injection of Three Modalities on Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2019 , 60, 1072	0.2	1
14	Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania. <i>Experimental and Therapeutic Medicine</i> , 2019 , 18, 4993-5000	2.1	12
13	Retinal Venous Occlusive Disease. 2020 , 1-43		
12	The Role of Optical Coherence Tomography in Anti-Vascular Endothelial Growth Factor Therapies. 2009 , 279-288		
11	Novel Therapeutic Strategies For Posterior Segment Neovascularization. 2008 , 445-526		
10	Treatment of Retinal Vein Occlusions. 2007 , 147-163		

9	Intravitreal bevacizumab: an analysis of the evidence. <i>Clinical Ophthalmology</i> , 2007 , 1, 273-84	2.5	7
8	Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. <i>Clinical Ophthalmology</i> , 2007 , 1, 149-55	2.5	9
7	Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study. <i>Molecular Vision</i> , 2011 , 17, 1044-55	2.3	12
6	Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial. <i>Journal of Ophthalmic and Vision Research</i> , 2011 , 6, 101-8	1.2	3
5	Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. <i>Journal of Ophthalmic and Vision Research</i> , 2012 , 7, 235-9	1.2	10
4	Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. <i>International Journal of Ophthalmology</i> , 2012 , 5, 759-70	1.4	5
3	The effects of bevacizumab treatment in a rat model of retinal ischemia and perfusion injury. <i>Molecular Vision</i> , 2018 , 24, 239-250	2.3	9
2	Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 824790	5.6	1
1	Retinal Venous Occlusive Disease. 2022 , 3019-3061		